Market Cap 5.13B
Revenue (ttm) 0.00
Net Income (ttm) -36.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 555,100
Avg Vol 168,128
Day's Range N/A - N/A
Shares Out 34.89M
Stochastic %K 65%
Beta -1.45
Analysts Strong Sell
Price Target $184.33

Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 246 6240
Address:
12750 High Bluff Drive, Suite 475, San Diego, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:36 AM
Actionable Trade Alert for $BLTE: Market Context: $BLTE is currently trading at $152.68, showing strong momentum but is overbought with an RSI of 78.67. The stock is above its 30-day (126.85) and 50-day (110.11) moving averages, indicating a bullish trend. However, the high of $161.32 in the last 60 days suggests potential resistance. Directional Bias: While the stock is in a strong upward trend, the high RSI indicates it may face a pullback. The range between the 60D high and low (161.32 - 68.21) provides a clear framework for potential targets. Trade Plan: - Suggested Entry: $152.68 - Stop Loss: $145.00 (approx. 5% below current price) - Take Profit Targets: 1. $160.00 (4.74% ROI) 2. $170.00 (11.29% ROI) 3. $179.00 (17.24% ROI) Monitor for price action and adjust stops accordingly. Aim for a disciplined exit strategy. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Doozio
Doozio Dec. 11 at 3:20 PM
$BLTE if no faatch 💣 lands?
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:39 AM
Actionable Trade Alert for $BLTE: Market Context: $BLTE is currently trading at $149.13, showing strong bullish momentum. The RSI at 65.81 indicates that the stock is nearing overbought territory but still has room for further upside. The proximity to the 60D high of $160.55 suggests potential resistance, while the MA30 (123.23) and MA50 (107.06) indicate a solid uptrend. Directional Bias: Bullish. The stock is above both the MA30 and MA50, confirming a positive trend. The current price is significantly above the MA30, indicating strong buying interest. Trade Plan: - Suggested Entry: $149.50 - Stop Loss: $139.00 (approx. 6.8% below entry) - Take Profit Targets: 1. $155.00 (3.3% gain) 2. $160.00 (7.1% gain) 3. $175.00 (17.3% gain) This plan offers a potential ROI of over 17% on the third target while maintaining a manageable risk. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 2:01 AM
$BLTE Current Stock Price: $149.34
0 · Reply
crazysnake
crazysnake Dec. 9 at 4:00 PM
$OCGN can patients do the ocu procedure and take $BLTE pills for GA and stagart they could take a big chunk of the market since they are going to get approved 3 years before ocu410st thinking about going back to pstv since its on steady climb
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:28 AM
Actionable Trade Alert for $BLTE: Market Context: $BLTE is currently trading at $147.07, showing strong momentum as indicated by an RSI of 66.69, suggesting it is nearing overbought territory but still has room for upward movement. The stock's recent performance is supported by its proximity to the 60D high of $160.55, providing a bullish sentiment. Directional Bias: The stock is above its 30-day moving average (MA30) of 121.29 and 50-day moving average (MA50) of 105.48, indicating a strong uptrend. The current price is significantly higher than the 60D low of 64.8, reinforcing the bullish outlook. Trade Plan: - Suggested Entry: $147.07 - Stop Loss: $138.00 (approx. 6% below entry) - Take Profit Targets: 1. $155.00 (5.4% ROI) 2. $165.00 (12.2% ROI) 3. $172.00 (17% ROI) This plan capitalizes on the upward momentum while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:27 AM
Actionable Trade Alert for $BLTE: Market Context: $BLTE is currently trading at $151.27, showing strong bullish momentum but with an RSI of 71.43, indicating it may be overbought. The stock is well above its MA30 (117.56) and MA50 (102.34), suggesting a strong upward trend. However, caution is advised due to potential pullbacks. Directional Bias: The stock is near its 60D high of 160.55, which could act as a resistance level. Given the current price and RSI, a correction might occur before further gains. Trade Plan: - Suggested Entry: $151.00 (slightly below current close) - Stop Loss: $144.48 (below recent support, approximately 5% risk) - Take Profit Targets: 1. $158.00 (4.6% gain) 2. $165.00 (9.1% gain) 3. $177.00 (17.1% gain) This plan provides a clear risk-reward ratio with potential for over 17% ROI on the third target. Monitor closely for price action around the entry and stop levels. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 11:02 PM
Actionable Trade Alert for $BLTE: Market Context: $BLTE is currently trading at $151.27, showing strong bullish momentum but with an RSI of 71.43, indicating it may be overbought. The stock is well above its MA30 (117.56) and MA50 (102.34), suggesting a strong upward trend. However, caution is advised due to potential pullbacks. Directional Bias: The stock is near its 60D high of 160.55, which could act as a resistance level. Given the current price and RSI, a correction might occur before further gains. Trade Plan: - Suggested Entry: $151.00 (slightly below current close) - Stop Loss: $144.48 (below recent support, approximately 5% risk) - Take Profit Targets: 1. $158.00 (4.6% gain) 2. $165.00 (9.1% gain) 3. $177.00 (17.1% gain) This plan provides a clear risk-reward ratio with potential for over 17% ROI on the third target. Monitor closely for price action around the entry and stop levels. https://privateprofiteers.com
0 · Reply
NetworkNewsWire
NetworkNewsWire Dec. 5 at 5:04 PM
InvestorNewsBreaks – $BLTE Prices $350M Underwritten Public Offering of ADSs https://ibn.fm/aSit4
0 · Reply
IN0V8
IN0V8 Dec. 3 at 3:45 PM
$BLTE Watch / Buy Benchmark raises target price to $187 from $132 Maxim Group raises target price to $200 from $140
0 · Reply
Latest News on BLTE
Why Belite Bio Stock Soared on Monday

Dec 1, 2025, 6:45 PM EST - 10 days ago

Why Belite Bio Stock Soared on Monday


Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 6:11 PM EST - 4 weeks ago

Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript


Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 11:36 PM EDT - 4 months ago

Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript


Belite Bio Announces Registered Direct Offering of $15 Million

Aug 7, 2025, 8:00 AM EDT - 4 months ago

Belite Bio Announces Registered Direct Offering of $15 Million


Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript

May 15, 2025, 4:59 AM EDT - 7 months ago

Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript


Belite Bio to Participate in Four Upcoming Investor Conferences

May 12, 2025, 8:00 AM EDT - 7 months ago

Belite Bio to Participate in Four Upcoming Investor Conferences


Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 6:40 PM EDT - 9 months ago

Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript


Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:28 PM EST - 1 year ago

Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript


Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 10:35 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript


Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:11 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript


Belite Bio Announces $25 Million Registered Direct Offering

Apr 25, 2024, 7:15 PM EDT - 1 year ago

Belite Bio Announces $25 Million Registered Direct Offering


Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 7:53 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:36 AM
Actionable Trade Alert for $BLTE: Market Context: $BLTE is currently trading at $152.68, showing strong momentum but is overbought with an RSI of 78.67. The stock is above its 30-day (126.85) and 50-day (110.11) moving averages, indicating a bullish trend. However, the high of $161.32 in the last 60 days suggests potential resistance. Directional Bias: While the stock is in a strong upward trend, the high RSI indicates it may face a pullback. The range between the 60D high and low (161.32 - 68.21) provides a clear framework for potential targets. Trade Plan: - Suggested Entry: $152.68 - Stop Loss: $145.00 (approx. 5% below current price) - Take Profit Targets: 1. $160.00 (4.74% ROI) 2. $170.00 (11.29% ROI) 3. $179.00 (17.24% ROI) Monitor for price action and adjust stops accordingly. Aim for a disciplined exit strategy. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Doozio
Doozio Dec. 11 at 3:20 PM
$BLTE if no faatch 💣 lands?
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:39 AM
Actionable Trade Alert for $BLTE: Market Context: $BLTE is currently trading at $149.13, showing strong bullish momentum. The RSI at 65.81 indicates that the stock is nearing overbought territory but still has room for further upside. The proximity to the 60D high of $160.55 suggests potential resistance, while the MA30 (123.23) and MA50 (107.06) indicate a solid uptrend. Directional Bias: Bullish. The stock is above both the MA30 and MA50, confirming a positive trend. The current price is significantly above the MA30, indicating strong buying interest. Trade Plan: - Suggested Entry: $149.50 - Stop Loss: $139.00 (approx. 6.8% below entry) - Take Profit Targets: 1. $155.00 (3.3% gain) 2. $160.00 (7.1% gain) 3. $175.00 (17.3% gain) This plan offers a potential ROI of over 17% on the third target while maintaining a manageable risk. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 2:01 AM
$BLTE Current Stock Price: $149.34
0 · Reply
crazysnake
crazysnake Dec. 9 at 4:00 PM
$OCGN can patients do the ocu procedure and take $BLTE pills for GA and stagart they could take a big chunk of the market since they are going to get approved 3 years before ocu410st thinking about going back to pstv since its on steady climb
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:28 AM
Actionable Trade Alert for $BLTE: Market Context: $BLTE is currently trading at $147.07, showing strong momentum as indicated by an RSI of 66.69, suggesting it is nearing overbought territory but still has room for upward movement. The stock's recent performance is supported by its proximity to the 60D high of $160.55, providing a bullish sentiment. Directional Bias: The stock is above its 30-day moving average (MA30) of 121.29 and 50-day moving average (MA50) of 105.48, indicating a strong uptrend. The current price is significantly higher than the 60D low of 64.8, reinforcing the bullish outlook. Trade Plan: - Suggested Entry: $147.07 - Stop Loss: $138.00 (approx. 6% below entry) - Take Profit Targets: 1. $155.00 (5.4% ROI) 2. $165.00 (12.2% ROI) 3. $172.00 (17% ROI) This plan capitalizes on the upward momentum while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:27 AM
Actionable Trade Alert for $BLTE: Market Context: $BLTE is currently trading at $151.27, showing strong bullish momentum but with an RSI of 71.43, indicating it may be overbought. The stock is well above its MA30 (117.56) and MA50 (102.34), suggesting a strong upward trend. However, caution is advised due to potential pullbacks. Directional Bias: The stock is near its 60D high of 160.55, which could act as a resistance level. Given the current price and RSI, a correction might occur before further gains. Trade Plan: - Suggested Entry: $151.00 (slightly below current close) - Stop Loss: $144.48 (below recent support, approximately 5% risk) - Take Profit Targets: 1. $158.00 (4.6% gain) 2. $165.00 (9.1% gain) 3. $177.00 (17.1% gain) This plan provides a clear risk-reward ratio with potential for over 17% ROI on the third target. Monitor closely for price action around the entry and stop levels. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 11:02 PM
Actionable Trade Alert for $BLTE: Market Context: $BLTE is currently trading at $151.27, showing strong bullish momentum but with an RSI of 71.43, indicating it may be overbought. The stock is well above its MA30 (117.56) and MA50 (102.34), suggesting a strong upward trend. However, caution is advised due to potential pullbacks. Directional Bias: The stock is near its 60D high of 160.55, which could act as a resistance level. Given the current price and RSI, a correction might occur before further gains. Trade Plan: - Suggested Entry: $151.00 (slightly below current close) - Stop Loss: $144.48 (below recent support, approximately 5% risk) - Take Profit Targets: 1. $158.00 (4.6% gain) 2. $165.00 (9.1% gain) 3. $177.00 (17.1% gain) This plan provides a clear risk-reward ratio with potential for over 17% ROI on the third target. Monitor closely for price action around the entry and stop levels. https://privateprofiteers.com
0 · Reply
NetworkNewsWire
NetworkNewsWire Dec. 5 at 5:04 PM
InvestorNewsBreaks – $BLTE Prices $350M Underwritten Public Offering of ADSs https://ibn.fm/aSit4
0 · Reply
IN0V8
IN0V8 Dec. 3 at 3:45 PM
$BLTE Watch / Buy Benchmark raises target price to $187 from $132 Maxim Group raises target price to $200 from $140
0 · Reply
SilverEagle
SilverEagle Dec. 3 at 3:12 PM
$BLTE yeah. Multiple hulks.
0 · Reply
CaptSparow
CaptSparow Dec. 3 at 3:30 AM
$OCGN BTW, when Ocugen hits, it should be a violent upside imho. $BLTE used as comparable.
1 · Reply
CaptSparow
CaptSparow Dec. 3 at 3:18 AM
$BLTE Congrats on Belite Bio 5 year chart. Early birds get the worm! Keep an eye on Ocugen for a likewise replication.
0 · Reply
RunnerSignals
RunnerSignals Dec. 2 at 8:20 PM
$BLTE $CDRE $CEVA $CHYM $CNTB Some serious fireworks here also! https://stocksrunner.com/news/2025-12-02-stock-upgrades-today-highlight-top-picks
0 · Reply
erevnon
erevnon Dec. 2 at 3:21 PM
Mizuho upgrades Belite Bio $BLTE from Neutral to Outperform and raises the price target from $105 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 3:05 PM
Mizuho has updated their rating for Belite Bio ( $BLTE ) to Outperform with a price target of 194.
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 2 at 2:05 PM
$BLTE (+1.9% pre) Belite Bio prices $350 million public offering at $154 per share https://ooc.bz/l/85971
0 · Reply
briefingcom
briefingcom Dec. 2 at 1:28 PM
$BLTE: Belite Bio (+7.7%) upgraded to Outperform from Neutral at Mizuho; tgt $194 https://www.briefing.com/calendars/updown?Filter=upgrades&utm_campaign=updown&utm_medium=social&utm_source=st&utm_content=link
0 · Reply
Pit1908
Pit1908 Dec. 2 at 7:36 AM
$OCGN Vs $BLTE Belite Bio reports positive Phase 3 data for an oral therapy against Stargardt disease, putting pressure on Ocugen's gene therapy approach. Markets are reassessing the prospects. The trigger for the current nervousness: Belite Bio has published successful data from its Phase 3 "DRAGON" trial. Tinlarebant, an oral therapy for Stargardt disease, showed promising results. For Ocugen, this is a warning sign. Because even though the news confirms the commercial potential of the Stargardt treatment, it simultaneously raises the bar significantly for new market entrants. This could also facilitate Ocugen's future FDA discussions.
1 · Reply
JarvisFlow
JarvisFlow Dec. 1 at 6:15 PM
HC Wainwright & Co. has adjusted their stance on Belite Bio ( $BLTE ), setting the rating to Buy with a target price of 98 → 185.
0 · Reply
b_dubs
b_dubs Dec. 1 at 5:09 PM
$BLTE Biotech co's that put out wildly promotional headline newswire releases tend to have a stench of pump.
0 · Reply
TheDizPlinTrader
TheDizPlinTrader Dec. 1 at 1:59 PM
$BLTE 🧬 1 Hour Levels Price: $154.00 Support: $149.00 Resistance: $163.50(Possibly)
0 · Reply